Skip to main content
Public beta This website is in public beta – please give your feedback.
Conditions

Endocrine neoplasia

Endocrine neoplasia is a condition that causes predisposition to tumours in the endocrine organs. There are several different forms caused by pathogenic variants in several different genes.

Overview

In endocrine neoplasia, tumours develop in the endocrine organs. Depending on the underlying affected gene, different tumours typically cluster together in recognised syndromes. The first tumour may arise in childhood, at which point genomic testing should always be considered. Tumour screening in known carriers of gene variants often starts at a young age.

Clinical features

The clinical features to look out for, as well as inheritance patterns and management considerations, depend on the specific syndrome.

  • Multiple endocrine neoplasia type 1 (MEN1), caused by variants in the MEN1 gene:
    • parathyroid tumours or parathyroid hyperplasia;
    • pituitary tumours;
    • pancreatic neuroendocrine tumours;
    • other endocrine tumours, such as tumours of the gastro-entero-pancreatic tract, adrenocortical tumours and bronchial carcinoid tumours; and
    • other non-endocrine tumours, such as facial angiofibromas, collagenoma and meningioma.
  • Multiple endocrine neoplasia type 2a (MEN2a) and multiple endocrine neoplasia type 2b (MEN2b), caused by variants in the RET gene:
    • medullary thyroid carcinoma;
    • phaeochromocytoma;
    • parathyroid tumours;
    • other non-endocrine manifestations, such as mucosal neuromas; and
    • other non-endocrine manifestations, such as skeletal anomalies (including Marfanoid habitus).
  • Multiple endocrine neoplasia type 4 (MEN4), caused by variants in the CDKN1B gene:
    • pituitary tumours;
    • parathyroid tumours; and
    • endocrine tumours of the gastro-entero-pancreatic tract.
  • Von-Hippel-Lindau syndrome, caused by variants in the VHL gene:
    • phaeochromocytoma;
    • paraganglioma;
    • pancreatic neuroendocrine tumours; and
    • other non-endocrine tumours, such as retinal angioma, spinal or cerebellar hemangioblastoma, renal cell carcinoma, endolymphatic sac tumours and papillary cystadenomas of the epididymis or broad ligament.
  • Phaeochromocytoma and paraganglioma, caused by pathogenic variants in the SDHx and NF1 genes:
    • phaeochromocytoma;
    • paraganglioma; and
    • other non-endocrine tumours, such as renal cell carcinoma and gastrointestinal stromal tumours.
  • Familial isolated pituitary adenoma, caused by pathogenic variants in the AIP and GPR101 genes:
    • pituitary tumours.
  • Carney complex, caused by pathogenic variants in the PRKAR1A gene:
    • pituitary hyperplasia and/or adenoma;
    • primary pigmented nodular adrenocortical disease;
    • thyroid carcinoma or benign nodules;
    • gonadal tumours;
    • other non-endocrine tumours, such as cardiac myxomas, dermatological, neurological, breast and musculoskeletal tumours; and
    • other non-endocrine manifestations, such as atypical skin pigmentation (lentigines).
  • McCune-Albright syndrome, caused by somatic mosaicism in the GNAS gene:
    • pituitary tumour and/or hyperplasia causing growth hormone excess;
    • adrenal hyperplasia causing cortisol excess;
    • thyroid enlargement (goitre) and benign nodules causing thyroid hormone excess;
    • other endocrine hyperfunction, such as precocious puberty (common first presentation in children) and FGF-23-mediated phosphaturia; and
    • other non-endocrine manifestations, such as polyostotic fibrous dysplasia and irregular-shaped café-au-lait skin lesions.
  • Pleuropulmonary blastoma-familial tumour and dysplasia syndrome, caused by pathogenic variants in the DICER1 gene:
    • pituitary blastoma causing Cushing syndrome;
    • pineoblastoma;
    • thyroid enlargement (goitre), benign nodules or carcinoma (papillary or follicular);
    • genitourinary or gynaecological neuroendocrine tumours;
    • ovarian embryonal rhabdomyosarcoma;
    • other non-endocrine manifestations, such as childhood pleuropulmonary blastoma or lung cysts, thoracic, uterine or cervical embryonal rhabdomyosarcoma, cystic nephroma, genitourinary sarcoma, ovarian sertoli leydig tumour, gynandroblastoma, ciliary body medulloepithelioma, nasal chondromesenchymal hamartoma and macrocephaly.

Resources

For clinicians

References:

For patients

↑ Back to top
  • Last reviewed: 08/08/2023
  • Next review due: 08/08/2025
  • Authors: Professor Márta Korbonits, Dr Ben Loughrey
  • Reviewers: Dr Emile Hendriks, Dr Louise Izatt, Dr Terri McVeigh